Stock Screener App

Gratuito -

1.70

2.30% -0.04

Geovax Labs Inc (GOVX)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione Frazionamento azionario

Geovax Labs Inc Borsa (GOVX) Ultime notizie

GeoVax announces $1.3 million direct offering By Investing.com - Investing.com

Earnings call: GeoVax reports progress on key vaccine trials - Investing.com Australia

Investing.com Australia

Earnings call: GeoVax reports progress on key vaccine trials - Investing.com Canada

Investing.com Canada

Earnings call: GeoVax reports progress on key vaccine trials - Investing.com UK

Investing.com UK

GeoVax Announces Collaboration with American Gene Technologies for HIV Functional Cure - Yahoo News UK

GeoVax to Conduct Partnering Meetings During BIO International Convention June 19-22 - Yahoo News UK

GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine

GlobeNewswire Inc.

GeoVax reports progress on next-gen Covid-19 vaccine - Investing.com India

Investing.com India

GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress - Yahoo Finance

GeoVax to Present at the 36th Annual Roth Conference - GlobeNewswire

GeoVax Labs, Inc. (NASDAQ:GOVX) Q4 2023 Earnings Call Transcript - Yahoo Finance

GeoVax Reports 2023 Year-End Financial Results and Provides Business Update

GlobeNewswire Inc.

InMed Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying

GeoVax to Present at the 2024 BIO CEO & Investor Conference

GlobeNewswire Inc.

GeoVax to Present at the 2024 BIO CEO & Investor Conference - Yahoo Finance

GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine ... - GlobeNewswire

GeoVax Labs Announces 1-for-15 Reverse Stock Split - TipRanks.com - TipRanks

GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

GlobeNewswire Inc.

GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement - GlobeNewswire

GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology

GlobeNewswire Inc.

GeoVax Announces Issuance of Malaria Vaccine Patent

GlobeNewswire Inc.

GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024

GlobeNewswire Inc.

GeoVax Labs And 2 Other Stocks Under $2 Insiders Are Buying

GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox - GlobeNewswire

GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress

GlobeNewswire Inc.

GeoVax to Participate in Upcoming December Investor Events

GlobeNewswire Inc.

GeoVax Presents Positive Phase 2 Trial Data for Next-Generation COVID-19 Vaccine at World Vaccine Congress - Onlymyhealth

GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based ... - Yahoo Finance

GeoVax Labs vaccinates first patients in trial of GEO-CM04S1 - Clinical Trials Arena

Clinical Trials Arena

GeoVax initiates trial of new Covid-19 vaccine GEO-CM04S1 - Clinical Trials Arena

Clinical Trials Arena

GeoVax, ABL Partner To Advance CGMP Production Of Vaccine Candidates - Contract Pharma

Contract Pharma

GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update - GlobeNewswire

City of Hope-developed COVID-19 vaccine found effective against variants - City of Hope

MULN: 5 Penny Stocks to Sell Before They Hit Zero - StockNews.com

GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq ... - GlobeNewswire

Covid Vaccine Developed by City of Hope Shows Success in Phase 1 Clinical Trial - Los Angeles Business Journal

Los Angeles Business Journal

GeoVax Announces Issuance of Cancer Vaccine Patent - GlobeNewswire

GeoVax vaccine targeting virus in two places shows promise; virus may become resistant to antibody drugs - Reuters

GeoVax commences dosing in Covid-19 booster shot trial - Clinical Trials Arena

Clinical Trials Arena

GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split - GlobeNewswire

GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market - GlobeNewswire

GeoVax and Sino Biological establish exclusive supply agreement for research grade bioreagents related to SARS ... - News-Medical.Net

News-Medical.Net

GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program - GlobeNewswire

GeoVax Announces Reverse Stock Split - GlobeNewswire

HIV Vaccine Candidate Launched Phase 1 Study — Precision Vaccinations News - Precision Vaccinations

Precision Vaccinations

GeoVax Reports on Vaccine Development Progress - Yahoo News UK

GeoVax to Discuss Zika Vaccine Development Progress at American Society for Virology Meeting - Yahoo News UK

$77.56

0.77%

$149.40

1.20%

$29.98

1.11%

$172.85

1.06%

$365.81

2.87%

$90.61

2.55%

Apri su Yahoo | Apri su Google | Aperto in Finviz